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 ABSTRACT
Objectives. To describe a case of rapidly relapsing chron-
ic inflammatory demyelinating polyradiculoneuropathy 
(CIDP) in the setting of positive serum IgG tubulin auto-
antibodies. 
Methods. We wrote a case report and performed a litera-
ture review of IgG tubulin autoantibodies and the use of 
rituximab in treatment resistant CIDP. 
Results. Our case report describes a 29-year-old woman 
with CIDP that was resistant to treatment with steroids, 
intravenous immunoglobulin, and plasma exchange. An ex-
tensive workup of her rapidly relapsing CIDP was negative, 
with the exception of positive serum IgG tubulin autoan-
tibodies. She ultimately stabilized on oral steroids, plasma 
exchange and rituximab, with a regular recurrence of weak-
ness occurring approximately every month that led to re-
hospitalization. 
Conclusions. Anti-tubulin antibodies could be a marker of 
a subtype of CIDP that is treatment resistant. We detail her 
clinical course to serve as an example for other cases of IgG 
tubulin autoantibody positive CIDP patients that could be 
described in the future.  
Keywords: CIDP, IgG tubulin autoantibodies, rituximab, 
demyelinating neuropathy.
Introduction
Chronic inflammatory demyelinating polyradiculoneu-
ropathy (CIDP) is a heterogeneous disease caused by auto-
immune destruction of the peripheral nerve myelin sheaths. 
Numerous antibodies felt to play a role in the underlying 
pathophysiology of this disease have been isolated in an at-
tempt to better understand it. 
In the literature, there is disagreement about whether 
anti-tubulin antibodies are markers for a subset of patient’s 
with CIDP. In 1993, Connolly et al published a paper on the 
detection of IgG and IgM tubulin autoantibodies in the sera 
of CIDP patients. Using ELISA, selective high-titer serum 
anti-B-tubulin antibodies occurred in up to 42% of patients 
with CIDP.1 In 1995, Van Schaik et al questioned their di-
agnostic value when only 3 of their 43 patients had positive 
antibodies using Western Blot.2 Manfredini et al found sim-
ilar results using an immunoblot technique, with high serum 
tubulin IgM titers in only 10.5% of CIDP patients.3 While 
the more recent studies indicate that anti-tubulin may not 
have good diagnostic value,2,3 one could also infer that anti-
tubulin CIDP may represent a rare form of the disease and 
could even warrant a different treatment approach. 
Here we describe a patient with positive anti-tubulin 
antibodies, whose diagnosis followed a somewhat atypical 
clinical and electrodiagnostic pattern for CIDP; resistant to 
treatment with steroids and IVIG. 
Case Presentation
A 29-year-old woman presented with two months of 
progressive upper and lower extremity weakness with in-
ability to walk, as well as numbness and tingling in the hands. 
On examination, she had diffuse muscle weakness, most 
prominent in the proximal upper extremities. Bulbar and 
respiratory muscles were spared. She was areflexic. Nerve 
conduction studies (NCS) showed a severe generalized sen-
sorimotor polyneuropathy with axonal and demyelinating 
features (Table 1). Needle-EMG showed active denervation 
in the proximal more than distal upper extremities, and to a 
lesser degree in the proximal and distal lower extremities. 
EMG suggested an acute to subacute process, with mini-
mal chronic features. The working diagnosis was CIDP. She 
completed five days of intravenous immunoglobulin (IVIG) 
and was discharged with improved strength in all extremi-
ties, however she remained areflexic. Figure 1 shows her 
MRC sum scores and treatments for each admission.4 
Four weeks later, she experienced worsening paresthe-
sias and weakness in upper extremities and was readmitted. 
Cerebrospinal fluid (CSF) showed protein of 78 mg/dL and 
cell count of 17 WBCs/mcL with 100% lymphocytes. She 
received four days of IVIG but failed to respond to the treat-
ment, and her examination at discharge was unchanged. 
Five days after discharge, she returned with profound 
weakness in all extremities and continued areflexia. NCS 
showed a primary demyelinating polyneuropathy. EMG 
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showed many muscles with markedly reduced recruitment, 
with absent or sparse active denervation, suggestive of in-
terval reinnervation since the prior study (Table 1). Workup 
for reversible, infectious, paraproteinemic and common 
autoimmune conditions were unrevealing. Repeat lumbar 
puncture demonstrated elevated CSF protein (61 mg/dL) 
and cell count (30 WBCs/mcL, with 99% lymphocytes). 
CSF testing for neurotropic viruses were negative. CSF cy-
tology and flow cytometry studies showed no evidence of 
malignancy. Pan-CT and transvaginal ultrasound were neg-
ative for malignancy. MRI brain and spine imaging showed 
only minimal enhancement in the upper cauda equina. A de-
myelinating polyneuropathy panel (Washington University 
in St. Louis) revealed elevated IgG anti-tubulin antibodies 
(20,000, ref range <2500). The IgM anti-tubulin titer was 
zero. Neurofascin 140 and 155, anti-ganglioside and contac-
tin-1 antibodies were negative. She received three days of 
IV solumedrol and five days of plasma exchange (PLEX). 
She clinically improved, with only residual numbness and 
tingling of her hands. 
Another relapse occurred eighteen days later. Her MRC 
sum score on admission was 44. On day three of admission, 
she worsened to an all-time low MRC sum of 8.  She then 
received PLEX, was started on an oral course of high-dose 
prednisone, and clinically improved to an MRC score of 32, 
albeit still not back to her strength on admission. 
She returned ten days later for recurring weakness, 
and the decision was made to administer IV rituximab 
900mg (2nd dose 2 weeks later) in addition to PLEX. Upon 
discharge, she regained her strength and was discharged 
home on 80mg per day of prednisone. Over the next six 
months she presented monthly with weakness in her arms 
> legs which improved with PLEX sessions to roughly 5/5 
strength everywhere. Rituximab was administered again six 
months after the last infusion. 
Discussion
Our patient meets the EFNS/PNS clinical and electro-
diagnostic criteria for typical CIDP, based on her recurrent 
symmetric  proximal and distal muscle weakness, sensory 
impairment, and areflexia in all extremities for more than 
two months,5 reduced motor nerve conduction velocities 
of >30% below the lower limit of normal in more than two 
nerves, increased motor distal latency of >50% above the 
upper limit of normal in two nerves, and absent F-waves in 
two nerves. 
Based on the EFNS/PNS criteria, CSF with elevated 
protein and absent pleocytosis (leukocytes <10 cells/µL) is 
supportive of CIDP. Our patient had elevated lymphocytes in 
both lumbar punctures, which could be because she received 
IVIG prior to both as IVIG has been linked to CSF pleocy-
tosis.6 The CSF pleocytosis from IVIG is associated with 
symptomatic aseptic meningitis in the literature, which our 
patient did not have.6 Additionally, prior studies suggest that 
a mild to moderate pleocytosis in the CSF does not exclude 
the diagnosis of CIDP. Lucke et al found that of 273 patients 
with CIDP based on the EFNS/PNS criteria, 14 of them had 
>10 leukocytes in the CSF. Most patients with CSF pleocyto-
Figure 1: MRC Sum Scores with Corresponding Treatments
MRC= Medical Research Council sum score (grades the sum of motor strength from 0 to 5 in bilateral deltoid, biceps, wrist extensor, 
iliopsoas, quadriceps femoris, and tibialis anterior for total score of 60 in patients with normal strength).
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sis had an acute to subacute presentation and responded to 
therapy with steroids and/or IVIG after six months.7
The assessment of this patient’s response to therapy 
has been guided by the clinical picture and treatment time 
to efficacy as documented in the existing literature. Howev-
er, there is subjectivity in our patient’s examinations as they 
were performed by different neurologists. The findings were 
consistent with the patient’s own subjective reports of wors-
Table 1: Serial NCS and Needle EMG Data
1st Admission 3rd admission
R median motor NCS: DML (ms)
                            CMAP amplitude (distal/proximal), µV
      CV (m/s)
5.05
5.3/3.6
33
sensory NCS: amplitude (µV) 12.9
F wave latency (ms) NR
L median Motor NCS: DML (ms)
       CMAP amplitude (distal/proximal), µV
       CV (m/s)
6.35
2.8/2.3
43
6.88
2.2/1.3
32
Sensory NCS: amplitude (µV) 4.9 NR
F wave latency (ms) NR 42.9
R ulnar Motor NCS: DML (ms)
        CMAP amplitude (distal/proximal), µV
        CV (m/s)
4.43
2.1/1.5
34
Sensory NCS:  amplitude (µV) 5.0
F wave latency (ms) 31.3
L ulnar Motor NCS: DML (ms)
        CMAP amplitude (distal/proximal), µV
        CV (m/s)
3.49
5.1/4.3
39
3.18
4.4/3.4
37
Sensory NCS: amplitude (µV) 23.7 11.5
F wave latency (ms) NR
L tibial Motor NCS: DML (ms)
       CMAP amplitude (distal/proximal), µV
       CV (m/s)
6.72
2.7/2.8
42
F wave latency (ms) 58.3
R peroneal Motor NCS: DML (ms)
       CMAP amplitude (ankle/fib head/pop), µV
       CV (fib head, pop) m/s
5.89
7.8/6.0/5.3
40/26
F wave latency (ms) NR
L peroneal Motor NCS:  DML (ms)
        CMAP amplitude (ankle/fib head/pop), µV
        CV (fib head, pop) m/s
6.15
4.9/4.2/3.9
41/28
F wave latency (ms) 60.5
NCS = nerve conduction study, EMG = electromyography, NR = no response, L = left, R = right, fib head= fibular head, pop = popliteal 
fossa, blank rows = not done. Abnormal values are bolded. 
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ening muscle weakness on admission and improved muscle 
weakness upon discharge. 
Additionally, we classified our patient’s disease process 
as “treatment-resistant,” because of her multiple relapses 
into recurrent inflammatory demyelinating disease despite 
standard therapies of corticosteroids, IVIG, and PLEX. 
Our decision to start rituximab was based on a random-
ized controlled trial by Roux et al, which showed that ritux-
imab administration in patients within a shorter duration of 
disease was associated with a better clinical response. The 
median time to response was six months, and 75% of the 
patients in that study responded to rituximab.8 It is notable, 
that most of those patients had an associated hematologic 
or autoimmune condition, which were absent in our patient. 
A second study of 13 patients with CIDP refractory to 
standard treatments found that on average, the response 
duration to rituximab was only two months. Of the five 
patients without a coexisting hematologic disease in this 
study, two responded to rituximab within two months and 
three did not respond at all. Three patients were able to stop 
their IVIG or plasmapheresis after starting rituximab.9 An-
other study showed similar findings.10
In a study looking at treatment-resistant patients with 
antibodies against Node of Ranvier proteins, disease dura-
tion in both patients that responded was less than one year 
at the time of initiation of rituximab.11
Compared to IgM anti-tubulin antibodies, the spec-
trum of clinical disorders associated with IgG anti-tubulin 
antibodies is even less well-defined. In Connolly’s origi-
nal 1993 paper out of 70 CIDP patients, there were twice 
as many IgM protein positive patients than IgG protein 
positive patients.1 This is different from van Schaik’s study, 
where 2 of the 43 patients had detectable IgG anti-tubulin 
antibodies and 1 had IgM anti-tubulin antibodies.2 Our pa-
tient would have been excluded from van Schaik’s study 
because they only included patients with a CSF cell count 
of < 10/mm.3 Our study also differs from van Schaik’s study 
because our patient’s IgG anti-tubulin antibodies were de-
tected using ELISA, the same method used in Connolly’s 
paper. In van Schaik’s study they used Western Blot, which 
is not as sensitive but has greater specificity. 
Of the 10 CIDP cases with anti-tubulin antibodies 
mentioned in the literature, the average age of onset was 
60. The weakness pattern was variable (proximal, distal, 
symmetric, asymmetric) and only 2 of them had positive 
IgG anti-tubulin antibodies.2,3,12,13 A case by Stubbs et al de-
scribed an IgM anti- tubulin antibody positive patient with 
a sensory-predominant polyneuropathy.12 No details about 
treatment outcome have been described in these cases. 
This may be the first detailed case report of the clinical 
course of an IgG anti-tubulin positive patient with CIDP. 
With the paucity of prior data about this CIDP variant, we 
are unsure if the tubulin autoantibodies are associated with 
the treatment-resistant nature of this disease or if the posi-
tive antibodies are an incidental finding. We hope that this 
report will inspire more research that can lead to faster rec-
ognition and treatment of refractory CIDP patients. 
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